Ergoteles’s Lexicon Pharmaceuticals LXRX Stock Holding History

Ergoteles’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-46,300	Closed	-$223K	–	1445
2021 Q3	$223K	Buy	+46,300	New	+$190K	0.01%	930

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ergoteles's LXRX Position: Q4 2021 in Review

Ergoteles sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2021, closing a stake of 46,300 shares — an estimated $223K sold.

Ergoteles first reported a position in LXRX in Q3 2021 and held it in 1 quarter. The position peaked at $223K in Q3 2021. 110 funds tracked by Wall St. Rank hold LXRX as of Q4 2021.

Ergoteles reported no remaining Lexicon Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Ergoteles sold 46,300 Lexicon Pharmaceuticals shares in Q4 2021, an estimated $223K.
Ergoteles first reported a position in Lexicon Pharmaceuticals in Q3 2021 and held it in 1 quarter.
Ergoteles's Lexicon Pharmaceuticals position peaked at $223K in Q3 2021.
110 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2021.

Based on Ergoteles's 13F filing for Q4 2021, filed 14 Feb 2022.